Cytek Cash Per Share from 2010 to 2026
| CTKB Stock | USD 4.36 0.14 3.32% |
Cash Per Share | First Reported 2010-12-31 | Previous Quarter 2.04725882 | Current Value 1.47 | Quarterly Volatility 0.96269636 |
Use the financial statements timeline for Cytek Biosciences to frame performance drivers and balance sheet structure. Track Tax Provision of 38.5 M, Net Interest Income of 2.9 M or Interest Income of 4 M and ratios such as Price To Sales Ratio of 3.04, Dividend Yield of 0.0 or PTB Ratio of 1.98 to align performance context with Cytek Biosciences Valuation and Volatility.
Cytek | Cash Per Share | Build AI portfolio with Cytek Stock |
Analyzing Cytek Biosciences's Cash Per Share over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Cash Per Share has evolved provides context for assessing Cytek Biosciences's current valuation and future prospects.
Latest Cytek Biosciences' Cash Per Share Growth Pattern
Below is the plot of the Cash Per Share of Cytek Biosciences over the last few years. It is Cytek Biosciences' Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 2.60 X | 10 Years Trend |
|
Cash Per Share |
| Timeline |
Cytek Cash Per Share Regression Statistics
| Arithmetic Mean | 0.96 | |
| Geometric Mean | 0.55 | |
| Coefficient Of Variation | 100.07 | |
| Mean Deviation | 0.87 | |
| Median | 0.23 | |
| Standard Deviation | 0.96 | |
| Sample Variance | 0.93 | |
| Range | 2.4996 | |
| R-Value | 0.79 | |
| Mean Square Error | 0.37 | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | 0.15 | |
| Total Sum of Squares | 14.83 |
Cytek Cash Per Share History
How Much Is Cytek Biosciences Worth?
Cytek Biosciences is a small-cap equity in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care categories. Operating leverage influences fair value range. We review the company from a portfolio-construction standpoint emphasizing diversification and stability.
Methodology
Unless otherwise specified, financial data for Cytek Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cytek (USA Stocks:CTKB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.
Assumptions
Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Cytek Biosciences may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Cytek Stock Analysis
Understanding Cytek Biosciences typically begins with financial statements and long-term trend review. Ratios and trend metrics help frame Cytek Biosciences' operating context. Below are reports that help frame Cytek Biosciences Stock in context:Use Cytek Biosciences Correlation to compare Cytek Biosciences against competitors. The view adds relative comparison context. Discover how to invest in Cytek Stock by reading our How to Buy Cytek Stock guide.Analysis related to Cytek Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Quarterly Earnings Growth 0.735 | Earnings Share -0.52 | Revenue Per Share | Quarterly Revenue Growth 0.081 | Return On Assets |
Cytek Biosciences market price can diverge from book value, the accounting figure shown on Cytek balance sheet. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Market price responds to sentiment, liquidity, and macro shifts, so gaps can appear. Valuation work aligns these measures into a single context.
It is useful to distinguish Cytek Biosciences' value from its trading price, which are computed with different methods. Context can include financial performance, operating efficiency, market trends, and peer comparisons. Market price reflects the current exchange level formed by active bids and offers.